186 related articles for article (PubMed ID: 28936581)
1. Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control.
Karlsson L; Mesterton J; Tepie MF; Intorcia M; Overbeek J; Ström O
Arch Osteoporos; 2017 Sep; 12(1):81. PubMed ID: 28936581
[TBL] [Abstract][Full Text] [Related]
2. Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice.
Thomas T; Horlait S; Ringe JD; Abelson A; Gold DT; Atlan P; Lange JL
Osteoporos Int; 2013 Jan; 24(1):263-9. PubMed ID: 22736069
[TBL] [Abstract][Full Text] [Related]
3. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
Abelson A; Ringe JD; Gold DT; Lange JL; Thomas T
Osteoporos Int; 2010 Jun; 21(6):1021-9. PubMed ID: 19722103
[TBL] [Abstract][Full Text] [Related]
5. Real-world effectiveness of osteoporosis treatments in Germany.
O'Kelly J; Bartsch R; Kossack N; Borchert J; Pignot M; Hadji P
Arch Osteoporos; 2022 Aug; 17(1):119. PubMed ID: 36044096
[TBL] [Abstract][Full Text] [Related]
6. Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
Eisman JA; Cortet B; Boolell M; Ionescu-Ittu R; Vekeman F; Heroux J; Thomasius F
Osteoporos Int; 2023 May; 34(5):977-991. PubMed ID: 36872338
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
8. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
Tan W; Sun J; Zhou L; Li Y; Wu X
J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
[TBL] [Abstract][Full Text] [Related]
9. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
Cadarette SM; Katz JN; Brookhart MA; Stürmer T; Stedman MR; Solomon DH
Ann Intern Med; 2008 May; 148(9):637-46. PubMed ID: 18458276
[TBL] [Abstract][Full Text] [Related]
10. Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis.
Thomasius F; Palacios S; Alam A; Boolell M; Vekeman F; Gauthier G
Osteoporos Int; 2022 Jan; 33(1):217-228. PubMed ID: 34490504
[TBL] [Abstract][Full Text] [Related]
11. Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.
Everts-Graber J; Bonel H; Lehmann D; Gahl B; Häuselmann H; Studer U; Ziswiler HR; Reichenbach S; Lehmann T
Osteoporos Int; 2023 Nov; 34(11):1961-1973. PubMed ID: 37493978
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
Bilezikian JP
Am J Med; 2009 Feb; 122(2 Suppl):S14-21. PubMed ID: 19187808
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
[TBL] [Abstract][Full Text] [Related]
14. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
15. Bone Mass Outcomes in Patients With Osteoporosis Treated With Risedronate After Alendronate Failure: a 12-Month Follow-Up Study.
Mendonça LT; Pinheiro MM; Szejnfeld VL; Castro CH
J Clin Densitom; 2017; 20(1):44-49. PubMed ID: 27616291
[TBL] [Abstract][Full Text] [Related]
16. The use of bisphosphonates in women: when to use and when to stop.
Gatti D; Adami S; Viapiana O; Rossini M
Expert Opin Pharmacother; 2015; 16(16):2409-21. PubMed ID: 26357942
[TBL] [Abstract][Full Text] [Related]
17. Risk of atypical femoral fracture during and after bisphosphonate use.
Schilcher J; Koeppen V; Aspenberg P; Michaëlsson K
Acta Orthop; 2015 Feb; 86(1):100-7. PubMed ID: 25582459
[TBL] [Abstract][Full Text] [Related]
18. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
Curtis JR; Westfall AO; Cheng H; Saag KG; Delzell E
Osteoporos Int; 2009 Jun; 20(6):973-8. PubMed ID: 18946630
[TBL] [Abstract][Full Text] [Related]
19. Preventing osteoporosis-related fractures: an overview.
Gass M; Dawson-Hughes B
Am J Med; 2006 Apr; 119(4 Suppl 1):S3-S11. PubMed ID: 16563939
[TBL] [Abstract][Full Text] [Related]
20. Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis.
Serrano AJ; Begoña L; Anitua E; Cobos R; Orive G
Gynecol Endocrinol; 2013 Dec; 29(12):1005-14. PubMed ID: 24063695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
